Constantin Volovăț

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

Florian Lordick, Yoon‐Koo Kang, Hyun Cheol Chung et al. · The Lancet Oncology · 2013 · 838 citations · Full text

Medicine, Oncology, Pharmacology +13

KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience

Carsten Bokemeyer, Igor Bondarenko, J.T. Hartmann et al. · Journal of Clinical Oncology · 2008 · 241 citations

Medicine, Oncology, Pharmacology +17

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

Peter Ruf, Michael Kluge, Michael Jäger et al. · British Journal of Clinical Pharmacology · 2010 · 89 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

<i>KRAS</i>,<i>NRAS</i>and<i>BRAF</i>mutations in Greek and Romanian patients with colorectal cancer: a cohort study

Șerban Negru, Eirini Papadopoulou, Angela Apessos et al. · BMJ Open · 2014 · 44 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

Pieter W. Kamphuisen, A.Y.Y. Lee, Guy Meyer et al. · Journal of Thrombosis and Haemostasis · 2018 · 40 citations · Full text

Medicine, Hematology, Oncology +17